摘要
目的:比较低剂量的布地奈德/福莫特罗(信必可都保)与中等剂量的布地奈德干粉(普米克都保)吸入治疗成年轻、中度哮喘患者的临床疗效和安全性。方法:62例哮喘患者分为A、B组,A组吸入信必可都保,B组吸入普米克都保,对照观察日间症状、夜间症状、最大呼气流量(PEF)、速效β2受体激动药使用次数的变化和不良反应。结果:2组治疗后日间症状和夜间症状(夜间憋醒次数)均有显著改善,速效β2受体激动药用量减少,PEF值及肺功能均有明显改善,且组间比较差异显著,不良反应轻微。结论:联合吸入低剂量的糖皮质激素和长效β2受体激动药为控制哮喘的较佳方案。加入低剂量长效β2受体激动药的疗效优于单一提高糖皮质激素的用量。
OBJECTIVE： To evaluate the efficacy and the safety of low dose budesonide/formoterol combination therapy vs.medium dose of budesonide（BUD） dry powder in the management of mild or moderate adult asthma.METHODS：A total of 62 patients with asthma were randomized to Group A（budesonide plus formcterol） or Group B（budesonide） .Main outcome measures： daytime symptom and nocturnal symptom, peak expiratory flow（PEF）, number of times of using rapid-acting β2 agonist and its ADR.RESULTS：After treatment,both groups had significant improvement in daytime symptom and nocturnal symptom（number of times of wakeup）,PEF value and lung function,and the dosage of rapid- acting β2 agonist was decreased, showing significant differences between the two groups.The ADR was light in degree .CONCLUSION： Inhalation therapy of low dose of glucocorticoid plus long- acting β2 agonist is an optimal choice in the management of asthma.The efficacy of glucocorticoid could be enhanced more by combination with low dose and long- acting β2 agonist than by simply increasing its own dose.
出处
《中国药房》
CAS
CSCD
北大核心
2007年第26期2048-2050,共3页
China Pharmacy
